Can THEM6 targeting stop resistance to prostate cancer treatment?
Prostate cancer (PCa) clinical management relies heavily on androgen‐deprivation therapy (ADT). However, despite experiencing initial clinical benefit, patients getting ADT for non‐resectable PCa eventually relapse and develop fatal castration‐resistant PCa (CRPC). Multiple mechanisms of acquired re...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2022-03-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202115504 |